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Background: Prion diseases are characterized by the accumulation of the pathogenic PrPSc protein, mainly in the
brain and the lymphoreticular system. Although prions multiply/accumulate in the lymph nodes without any
detectable pathology, transcriptional changes in this tissue may reflect biological processes that contribute to the
molecular pathogenesis of prion diseases. Little is known about the molecular processes that occur in the
lymphoreticular system in early and late stages of prion disease. We performed a microarray-based study to identify
genes that are differentially expressed at different disease stages in the mesenteric lymph node of sheep naturally
infected with scrapie. Oligo DNA microarrays were used to identify gene-expression profiles in the early/middle
(preclinical) and late (clinical) stages of the disease.
Results: In the clinical stage of the disease, we detected 105 genes that were differentially expressed (≥2-fold
change in expression). Of these, 43 were upregulated and 62 downregulated as compared with age-matched
negative controls. Fewer genes (50) were differentially expressed in the preclinical stage of the disease. Gene
Ontology enrichment analysis revealed that the differentially expressed genes were largely associated with the
following terms: glycoprotein, extracellular region, disulfide bond, cell cycle and extracellular matrix. Moreover, some
of the annotated genes could be grouped into 3 specific signaling pathways: focal adhesion, PPAR signaling and
ECM-receptor interaction. We discuss the relationship between the observed gene expression profiles and PrPSc
deposition and the potential involvement in the pathogenesis of scrapie of 7 specific differentially expressed genes
whose expression levels were confirmed by real time-PCR.
Conclusions: The present findings identify new genes that may be involved in the pathogenesis of natural scrapie
infection in the lymphoreticular system, and confirm previous reports describing scrapie-induced alterations in the
expression of genes involved in protein misfolding, angiogenesis and the oxidative stress response. Further studies
will be necessary to determine the role of these genes in prion replication, dissemination and in the response of
the organism to this disease.
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Transmissible spongiform encephalopathies (TSEs) or
prion diseases are a group of fatal neurodegenerative dis-
orders of animals and humans. TSEs generally involve
long incubation periods, which in humans can span sev-
eral decades [1]. These diseases are characterized by the
accumulation, mainly in nervous and lymphoreticular* Correspondence: rbolea@unizar.es
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reproduction in any medium, provided the ortissues, of an abnormal isoform (PrPSc) of a normal
host-coded cell surface glycoprotein (PrPc). Pathogenesis
typically involves a triad of histological events; vacuol-
ation, neuronal loss and astrocytosis. PrPSc accumulation
is currently considered the only reliable biochemical
marker for this group of diseases [2].
Scrapie is a TSE that naturally affects sheep and goats.
Ovine scrapie is a useful model in which to study the
pathogenic mechanisms of the variant Creutzfeldt Jakob
disease (vCJD), which affects humans [3]. Like vCJD,
classical scrapie is associated with widespread tissue in-
fectivity, mainly in the central nervous system (CNS),d. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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system (LRS) [4].
Mesenteric lymph nodes are one of the first tissues of
the LRS in which PrPSc accumulates during the preclin-
ical disease stage in naturally infected sheep [5,6], al-
though this process strongly depends on the animal’s
PRNP genotype. Subsequently, other LRS tissues are rap-
idly and near simultaneously exposed to infectivity, pre-
sumably by circulating prions. In the clinical stages of
the disease and in all susceptible PRNP genotypes except
VRQ/ARR, infectivity and PrPSc accumulation are gener-
ally observed throughout all lymphoid tissues, except for
the thymus [7]. Follicular dendritic cells (FDCs) may be
necessary for prion propagation within the LRS [8], and
macrophages and tingible body macrophages (TBMs) of
the LRS have been identified as reservoirs of the infec-
tious agents of TSEs [4,9].
The molecular mechanisms that underlie the uptake of
the infectious prion agent and the progression of the dis-
ease remain largely unknown. Given the complexity and
multifactorial nature of the spread and accumulation of
the infectious agent, we and others have used gene ex-
pression analysis platforms to identify signaling pathways
that are altered during PrPSc accumulation and subse-
quent neurodegeneration. This approach facilitates the
identification of potential biomarkers and drug targets in
natural ovine scrapie [10,11] and in experimental murine
scrapie models [12-14].
Few gene expression-profiling studies have investigated
changes in the lymphoreticular system in sheep with nat-
ural scrapie; most have been performed using murine
models [15,16] or ileal Peyer’s patches from orally inocu-
lated lambs [17]. In the present study, we used an ovine
microarray technology to identify transcriptional changes
in the mesenteric lymph node in both clinical and pre-
clinical disease stages in sheep that were naturally in-
fected with scrapie. This is the first transcriptome-wide
expression profiling study of the lymphoreticular system
in sheep with natural scrapie.
Methods
Ethics statement
This study was approved by the Ethics Committee for
Animal Experiments of the University of Zaragoza (Permit
Number: PI02/08) and was carried out in strict accord-
ance with the recommendations for the care and use of
experimental animals and in agreement with national law
(R.D. 1201/2005).
Animals, necropsy, tissue collection and RNA isolation
All details of the animals used and the necropsy and
RNA isolation procedures have been previously reported
[10,11]. Briefly, we used a 17 female ARQ/ARQ Rasa
Aragonesa sheep (aged 1-6 years). Eleven animals wereobtained from scrapie-infected flocks from several loca-
tions in Aragon (Spain); 7 of these exhibited clinical signs
of scrapie while 4 were preclinical. Six animals were se-
lected from flocks located in scrapie-free areas and were
used as breed, genotype and age-matched controls.
Sheep in the clinical disease stage were identified by
assessing clinical signs associated with the disease [18].
Third eyelid [18] and rectal mucosa biopsies [19] were
used to confirm this diagnosis and to identify animals in
the preclinical disease stage. Postmortem examinations
revealed no additional pathological findings. Mesenteric
lymph node samples were divided into 2 halves; one was
snap-frozen in liquid nitrogen and stored at −80°C until
RNA extraction, and the other was formalin-fixed and
paraffin-embedded for further histopathological analysis.
Total RNA isolation, purification and quality control
were performed as previously described [10,11].
Immunohistochemical detection of PrPSc
Immunohistochemical (IHC) analyses were performed
using serial sections. Prion protein was detected, after for-
mic acid treatment and proteinase K digestion, using the
monoclonal primary antibody L42 (1:500; R-Biopharm), as
previously described [20]. Negative controls were per-
formed omitting the primary antibody from control and
scrapie sections.
The preparations were microscopically examined and
global PrPSc deposition was scored by quantifying the
proportion of lymphoid follicles with PrPSc deposits as
follows: 1, <20%; 2, 20-50%; 3, >50% [19]. Significant dif-
ferences between clinical, preclinical and control groups
were identified using the Kruskal-Wallis test.
Microarray hybridization
The custom CVI 4x44K microarrays used in this study
contained custom eArray-designed 60-mer probes of
previously sequenced, normalized and subtracted cDNA
libraries of ovine Peyer’s Patch, obex and tonsil, supple-
mented with the publicly available Ovis aries transcripts
from the NCBI/EBI databases and the Agilent O. aries
transcript catalog. All arrays were printed using Sureprint
technology (Agilent Technologies).
Preparation of the labeled cDNA probes and subsequent
Genechip hybridizations were performed in accordance
with the Agilent Technologies One-Color Microarray-
Based Gene Expression Analysis guidelines, as previously
described [10,11]. Hybridizations were performed in du-
plicate, resulting in 14 microarrays for the clinical sam-
ples, 8 microarrays for the preclinical samples and 12 for
the negative control samples. Microarrays were scanned
using the GenePix 4200AL Scanner (Axon Instruments)
and GenePix Pro 6.0 software and the hybridization data
were extracted using Agilent Feature Extraction software
v9.5.3.1 (Agilent Technologies) before processing with
Table 1 Genes analyzed by quantitative real-time PCR
Gene Primer sequence Size
(bp)
Accession number
BBOX1 F: TGCAAACAATGTGGCTTACACA 85 NM_001101881.2**
R: AAGCTGAACCCCAGGTGGAT
CP F: GCAGCCAGATACTGCAGGGAC 97 NM_001009733.1*
R: CCCGCACTGGCTCACAGTATAT
PFDN2 F: GCAGGTAATTGCTGGCTTCAA 84 NM_001080221.2**
R: TTCAACTCCATCTCCAGCTCAG
PSMA7 F: TAATGTCTGCATGGCATTCGC 81 NM_001034233.2**
R: TGGCTCTGGCATTCCACC
SERPINE1 F: TGTACGTGTCGCAGGCGC 83 NM_174137.2**
R: TACAAGGGCTGTGGAGGAGGAC
UCHL1 F: AACTTGATGGACGGATGCCTT 84 NM_001046172.2**
R: TGCAGACCTTGGCAGCGT
VEGFA F: GGGCTGCTGTAATGACGAAAGT 81 NM_001025110.1*
R: GGTTTGATCCGCATAATCTGCA
*Ovine cDNA.
**Bovine cDNA.
Primers (F, forward; R, reverse) used for gene amplification, amplicon size and
GenBank accession numbers for the bovine cDNA sequences used for primer
design.
Filali et al. BMC Genomics 2014, 15:59 Page 3 of 17
http://www.biomedcentral.com/1471-2164/15/59GeneSpring GX 10.0.2 (Agilent Technologies). Chip values
were normalized using the 75th percentile value and ex-
pression levels were calculated. Global mesenteric lymph
node gene expression profiles for the clinical and preclin-
ical disease stages were compared with the negative
controls using a linear model that accounts for both tech-
nical (random animal effects) and biological replicates
(disease effects). A multiple testing correction developed
by Benjamini and Hochberg was also applied. Only genes
that exhibited at least a 2-fold change (FC) in expression
between healthy and infected animals and had a P-value ≤
0.05 were selected. These genes were clustered according
to their Euclidean distance coefficient using PermutMatrix
software [21]. A Megablast search of the GenBank data-
base nr/nt was performed to identify genes that were simi-
lar to the differentially expressed probes. The molecular
functions of the genes were classified according to Gene
Ontology (GO) using an on-line functional annotation
tool (DAVID Bioinformatics Resources 6.7; NIAID/NIH,
USA) [22,23].
Quantitative real-time PCR
Quantitative real-time PCR (qRT-PCR) was performed to
confirm the expression of 7 genes. Genes were selected
based on previous studies describing their association with
prion and other neurodegenerative diseases or their
potential role in protein misfolding repair, the promotion
of angiogenesis, or the systemic response of the organism
to infection [24-30]. The PCR primer sequences used for
the quantification of the genes encoding butyrobetaine
(gamma), 2-oxoglutarate dioxygenase 1 (BBOX1), cerulo-
plasmin (ferroxidase) (CP), prefoldin subunit 2 (PFDN2),
proteasome subunit, alpha type, 7 (PSMA7), serpin peptid-
ase inhibitor, clade E (nexin, plasminogen activator inhibitor
type 1), member 1 (SERPINE1), ubiquitin carboxyl-terminal
esterase L1 (ubiquitin thiolesterase) (UCHL1) and vascular
endothelial growth factor A (VEGFA) are shown in Table 1.
The RNA samples used for qRT-PCR were the same as
those used for microarray experiments. The qRT-PCR
assays were designed using Primer Express 2.0 software
(Applied Biosystems) to select appropriate primer se-
quences from known ovine or bovine sequences. When-
ever possible, the exon-exon border was included to
prevent amplification of genomic DNA in the PCR reac-
tion. Complementary DNA (cDNA) was synthesized from
1 μg RNA using random hexamer primers with the Super-
script First Standard Synthesis System for RT-PCR (Invi-
trogen). To confirm the elimination of any remaining
DNA, reverse transcription was performed with and with-
out the enzyme.
Quantitative RT-PCR was performed using SYBR®
Green (PE Applied Biosystems) assays as previously de-
scribed [10,11]. To improve the normalization accuracy,
a normalization factor (NF) was used to determine theexpression level of each gene in each sample, as previ-
ously described [31]. The NF was calculated using the
geometric mean expression of 3 housekeeping genes
(GAPDH, G6PDH and RPL32). The primers and PCR
conditions used for the amplification of these house-
keeping genes have been described previously [31,32].
The quantitative results obtained from the qRT-PCR
assays were expressed as FC with respect to controls.
Significant differences between groups were determined
using a Student’s t-test (P < 0.05).
The relationship between neuropathology and gene
expression
We used 2 different models to quantify the relationships
between the PrPSc deposition and gene expression. We
first used a simple regression model,
yi ¼ μþ bpi þ ei
where yi is the gene expression data for the i
th individual
for each gene, μ is the general mean, b is slope of the re-
gression analysis, pi is the PrP
Sc deposition for the ith in-
dividual and ei is the residual. In addition, we used
another model,
yij ¼ μþ Ti þ bpij þ eij
which includes a systematic effect associated with the 3
categories (Preclinical, Clinical and Healthy). Here yij
represents the gene expression for the jth individual at
the ith category, Ti the effects of the i
th treatment, pij the
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nificance of the slope associated with PrPSc deposition
was determined for both models. Analyses were per-
formed using the R project for Statistical Computing.
Results
PrPSc deposition in lymphoid tissue
The accumulation of PrPSc in the LRS was consistent
with the features of classical scrapie. PrPSc was detected
within the primary and secondary lymphoid follicles of
the lymph nodes. Some cells in the follicular mantle and
paracortical area were also PrPSc-positive. Interfollicular
and sinusal cells were rarely labeled. As seen in other
LRS tissues, distinct granular immunolabeling was de-
tected in the cytoplasm of tingible body macrophages inFigure 1 Semi-quantitative assessment of PrPSc deposition in mesent
scrapie sheep. Deposition was evaluated on a scale of 0 (negative) to 5 (m
between control and scrapie groups using a Kruskal-Wallis test (**P < 0.01)
(B) and clinical (C) scrapie sheep.both the dark and light zones of the lymphoid follicles.
A granular deposition was observed in the vicinity of
round cells, which were morphologically similar to im-
mature B lymphocytes (Figure 1). None of the control
animals displayed PrPSc immunostaining and no statisti-
cally significant differences were observed between the 2
scrapie-infected groups (preclinical and clinical).
Identification of differentially expressed genes in the
mesenteric lymph node of sheep with natural scrapie
A total of 234 probe sets displayed significant differences
in expression of 2-fold or more between the control and
scrapie (preclinical and clinical) groups. While the genes
of Ovis aries are relatively poorly annotated, we used
BLAST searches against publicly available databases toeric lymph nodes samples from control, preclinical and clinical
aximum staining intensity). Significant differences were detected
(A). PrPSc deposition in the mesenteric lymph node from preclinical
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of 234 differentially expressed probes. Some of these 234
probes encoded the same gene. The microarray data
were deposited in ArrayExpress and assigned the acces-
sion number E-MTAB-1346.
Based on the GO analysis of human homologs, 139
genes had known functions (Table 2), of which 105 were
differentially regulated in clinical scrapie-infected sheep
(43 upregulated and 62 downregulated) and 50 in pre-
clinical scrapie-infected sheep (12 upregulated and 38
downregulated). The functional groups with the highest
p values in the enrichment analysis are shown in Table 2;
the most relevant terms were glycoprotein, extracellular
region, disulfide bond and cell cycle. In addition, some of
the annotated genes were grouped in 3 signaling path-
ways: focal adhesion, PPAR signaling pathway and ECM-
receptor interaction (Table 3). After hierarchical clustering
using the expression levels of all annotated genes, we were
able to discriminate the 3 experimental groups: clinical,
preclinical and healthy (Figure 2).
The relatively low number of animals analyzed and the
fact that they were obtained from different geographical
locations may limit the statistical power of our study.
However, it is difficult to perform this kind of study with
a larger number of animals due to the paucity of natural
scrapie cases. Moreover, finding negative age-matched
controls with the same PRNP genotype within the same
scrapie-affected flocks is not possible since the disease
attack-rate in these animals is close to 100%.
Validation of gene expression profiling by quantitative
RT-PCR
To confirm the microarray results, the expression of 7
genes (BBOX1, CP, PFDN2, PSMA7, SERPINE1, UCHL1
and VEGFA) was analyzed by qRT-PCR. The expression
of 4 of the selected targets (BBOX1, PFDN2, PSMA7
and UCHL1) was altered in the same direction in both
the clinical and preclinical stages of scrapie disease. Ex-
pression levels of the other 3 genes (CP, SERPINE1 and
VEGFA) were altered in opposite directions in the clin-
ical and preclinical stages, respectively. In all cases, qRT-
PCR confirmed the changes observed in the microarray
hybridizations (Figure 3), revealing statistically signifi-
cant differences between control and scrapie groups.
Identification of prion deposition-related genes
Two regression models were used to identify genes asso-
ciated with prion deposition. One is a regression model
that relates gene expression with prion deposition scores
regardless of group (Preclinical, Clinical or Healthy),
while the other includes a systematic effect associated
with the 3 different animal categories and analyzes the
remaining variation after subtracting the variability asso-
ciated with each of the 3 groups. Natural conditionsnormally display high variability within groups. Using
these regression analyses we identified genes whose ex-
pression was associated with prion deposition, even if
the changes in expression were not significant. We iden-
tified 96 genes with known functions whose expression
was significantly associated with PrPSc deposition in
both regression models (Figure 4). The slope value rep-
resented was obtained using the second regression
model. The gene ontology analysis revealed that genes
associated with prion deposition were involved in DNA
binding, the generation of precursor metabolites and en-
ergy, ion binding, catabolic process and kinase functions.
Only statistically significant slopes (p < 0.05) for both as-
sociation models are presented in Figure 4.
Discussion
Mesenteric lymph nodes are one of the first organs in
which PrPSc accumulates [5]. To the best of our know-
ledge, ours is the first study to use gene expression
microarray technology to analyze mesenteric lymph
nodes from naturally-infected sheep during the preclin-
ical and clinical stages of scrapie.
Our microarray hybridization analysis identified 139
annotated genes of known functions that exhibited
changes in expression of 2-fold or more with respect to
controls during at least one of the 2 disease stages ana-
lyzed. Of these 139 genes, 105 were differentially regu-
lated in clinical scrapie-infected sheep and 50 in
preclinical scrapie-infected sheep. These findings indi-
cate that in the early disease stages, fewer genes are acti-
vated or the changes in expression are not sufficiently
large to be detected by microarray. PrPSc accumulation
in MLN peaked during the preclinical phase of scrapie
(Figure 1), indicating that dysregulated genes that were
not common to both disease stages could not be specif-
ically linked to the prion accumulation process.
Prion infection of neural cell lines has revealed a lim-
ited transcriptional response and clear differences in
transcriptional profiles between different cell lines and
between cell cultures and whole brains from infected
mice [35-37]. Similarly, our results differ from the pro-
files described in the brains of sheep with natural scrapie
[10,11], indicating the absence of universal changes asso-
ciated with prion infection.
The differentially expressed genes identified in the
present study encode proteins located in almost all sub-
cellular locations: membranes (glycoproteins), the extra-
cellular matrix, the cytoplasm and chromosomes. These
proteins participate in general cell processes such as the
cell cycle, apoptosis, alternative splicing and chromo-
some condensation. Genes associated with glycoprotein
metabolism, the extracellular matrix and the cell cycle
have been previously detected in leukocyte-depleted
splenic cells from mice infected with scrapie [16]. We
Table 2 GO terms for differentially expressed genes
Term P value ProbeName FC (C vs NC) FC (PC vs NC) Gene symbol Gene name Citation
Glycoprotein 5.16E-04 A_70_P042906 2.22 1.00 AQP1 Aquaporin 1 (Colton blood group)
CUST_5666_PI375351158 −2.02 −1.16 AQP4 Aquaporin 4 [10]
A_70_P041077 2.09 1.39 PTGER3 Prostaglandin E receptor 3 (subtype EP3)
A_70_P030356 1.48 −2.06 SLC11A1 Solute carrier family 11 (proton-coupled divalent
metal ion transporters), member 1
A_70_P051037 −2.09 2.85 SLC2A5 Solute carrier family 2 (facilitated glucose/fructose
transporter), member 5
[10]
A_70_P036386 −1.29 −2.01 UCHL1* Ubiquitin carboxyl-terminal esterase L1 (ubiquitin thiolesterase)
Extracellular region 5.37E-04 CUST_2502_PI375351158 2.26 2.76 BMPER BMP binding endothelial regulator
A_70_P006426 4.26 1.06 FGL1 Fibrinogen-like 1
A_70_P069571 2.05 1.93 FIBIN Fin bud initiation factor homolog (zebrafish)
A_70_P038041 1.95 −3.63 HP Haptoglobin [10]
CUST_3439_PI375351158 2.70 1.38 PIGR Polymeric immunoglobulin receptor
A_70_P035871 1.03 −3.29 SERPINE1* Serpin peptidase inhibitor, clade E (nexin, plasminogen
activator inhibitor type 1), member 1
A_70_P039451 −1.57 −2.28 SFN Stratifin
A_70_P050922 2.19 −1.06 VEGFA* Vascular endothelial growth factor A
Disulfide bond 1.10E-03 CUST_598_PI375351158 2.28 1.33 FABP5 Fatty acid binding protein 5 (psoriasis-associated)
A_70_P070736 −3.83 −1.06 TXNRD1 Thioredoxin reductase 1
Cell cycle 1.17E-03 A_70_P058586 −2.85 −1.55 PSMA7* Proteasome (prosome, macropain) subunit, alpha type, 7
A_70_P057841 −1.61 −2.51 BRCA2 Breast cancer 2, early onset
A_70_P053686 1.11 −2.01 CCNDBP1 Cyclin D-type binding-protein 1
A_70_P060136 −1.48 −2.04 CGREF1 Cell growth regulator with EF-hand domain 1
A_70_P027076 −2.79 −1.28 EID1 EP300 interacting inhibitor of differentiation 1
A_70_P007666 −2.87 −1.61 KIF2C Kinesin family member 2C
A_70_P011891 −2.34 −1.29 MND1 Meiotic nuclear divisions 1 homolog (S. cerevisiae)
A_70_P009551 −2.13 −1.07 NCAPG Non-SMC condensin I complex, subunit G
A_70_P037556 −2.12 1.01 NDC80 NDC80 homolog, kinetochore complex
component (S. cerevisiae)
A_70_P034256 −2.20 1.05 TFDP2 Transcription factor Dp-2 (E2F dimerization partner 2)
A_70_P061801 −2.01 −1.39 UBE2C Ubiquitin-conjugating enzyme E2C
Condensed chromosome 1.71E-03 CUST_7895_PI375351158 −2.79 −1.15 HMGB1 High-mobility group box 1
A_70_P003816 −2.20 −1.67 TEX12 Testis expressed 12
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Table 2 GO terms for differentially expressed genes (Continued)
Alternative splicing 2.04E-03 A_70_P059171 −2.57 −2.17 CLTA Clathrin, light chain (Lca)
A_70_P033441 1.13 2.27 MEST Mesoderm specific transcript homolog (mouse)
A_70_P039536 −2.86 −1.34 MX1 Myxovirus (influenza virus) resistance 1,
interferon-inducible protein p78 (mouse)
A_70_P060791 2.25 1.38 PEG3 Paternally expressed 3
A_70_P015446 −1.52 −2.13 UNC50 Unc-50 homolog (C. elegans)
Chromosome 2.20E-03 A_70_P065046 −2.68 −1.32 JRKL Jerky homolog-like (mouse)
A_70_P040916 −2.62 −1.67 ORC1L Origin recognition complex, subunit 1-like (yeast)
CUST_12205_PI375351158 −2.04 −1.20 TOP2A Topoisomerase (DNA) II alpha 170 kDa [33]
Extracellular matrix 3.15E-03 A_70_P021711 −2.19 −1.69 COL1A1 Collagen, type I, alpha 1 [10,16]
CUST_11292_PI375351158 2.40 1.12 CRISPLD2 Cysteine-rich secretory protein LCCL domain containing 2
A_70_P007356 2.20 1.26 DCN Decorin [10,16]
CUST_7449_PI375351158 1.46 −2.05 DPT Dermatopontin
A_70_P032476 2.45 −1.35 MFAP5 Microfibrillar associated protein 5 [10]
A_70_P058626 2.27 1.13 VWF Von Willebrand factor
Signal peptide 3.25E-03 A_70_P064081 2.44 −2.18 CA4 Carbonic anhydrase IV
A_70_P061221 1.20 −2.43 P4HA1 Prolyl 4-hydroxylase, alpha polypeptide I [10,11]
A_70_P040831 −2.09 −1.07 SELL Selectin L
Tumor suppressor 1.47E-02 A_70_P035971 2.05 −1.75 VWA5A Von Willebrand factor A domain containing 5A
A_70_P026737 3.11 −1.41 WT1 Wilms tumor 1
A_70_P061691 1.26 2.26 HPGD Hydroxyprostaglandin dehydrogenase 15-(NAD)
Cytoplasm 1.82E-02 A_70_P016337 −1.78 −2.72 HMMR Hyaluronan-mediated motility receptor (RHAMM)
CUST_12176_PI375351158 −1.04 −2.92 ACTG2 Actin, gamma 2, smooth muscle, enteric
A_70_P019656 1.01 3.59 ADH1A Alcohol dehydrogenase 1A (class I), alpha polypeptide
A_70_P045301 3.70 2.33 BBOX1* Butyrobetaine (gamma), 2-oxoglutarate dioxygenase
(gamma-butyrobetaine hydroxylase) 1
A_70_P069971 −2.09 −1.73 CDC42EP5 CDC42 effector protein (Rho GTPase binding) 5
CUST_5823_PI375351158 1.12 2.07 NIN Ninein (GSK3B interacting protein)
A_70_P018021 −3.25 −1.15 PAIP2 Poly(A) binding protein interacting protein 2
A_70_P054126 −2.16 −1.11 PHAX Phosphorylated adaptor for RNA export
A_70_P044246 1.26 −2.14 RRAGD Ras-related GTP binding D
A_70_P055106 2.05 1.07 SORBS2 Sorbin and SH3 domain containing 2
A_70_P025726 −2.39 −1.60 STMN2 Stathmin-like 2
A_70_P060991 −2.80 1.21 CA3 Carbonic anhydrase III, muscle specific
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Table 2 GO terms for differentially expressed genes (Continued)
Fatty acid metabolism 2.26E-02 CUST_8730_PI375351158 1.06 −2.05 ACSL4 Acyl-CoA synthetase long-chain family member 4
A_70_P039986 −1.27 2.39 SLC27A2 Solute carrier family 27 (fatty acid transporter), member 2
Phosphatidic acid
metabolic process
2.86E-02 A_70_P039726 −2.50 −1.10 AGPAT1 1-acylglycerol-3-phosphate O-acyltransferase 1
(lysophosphatidic acid acyltransferase, alpha)
A_70_P025121 −3.34 −1.30 PLA2G2A Phospholipase A2, group IIA (platelets, synovial fluid)
Protein dimerization activity 2.91E-02 CUST_206_PI396851701 2.04 −2.28 FOS v-fos FBJ murine osteosarcoma viral oncogene homolog [10,11,33]
CUST_10535_PI375351158 −2.41 −2.41 NFE2L1 Nuclear factor (erythroid-derived 2)-like 1
Zinc finger, C2H2-type 3.09E-02 CUST_13307_PI375351158 −2.34 −1.26 ATMIN ATM interactor
A_70_P036056 −2.65 −1.71 KLF6 Kruppel-like factor 6
A_70_P065371 −2.27 −1.13 ZCCHC6 Zinc finger, CCHC domain containing 6
A_70_P014286 1.33 2.01 ZNF45 Zinc finger protein 45
Cytoplasmic
membrane-bounded
vesicle
3.21E-02 A_70_P062831 −3.71 −1.48 EHD3 EH-domain containing 3
A_70_P044621 2.27 −1.04 MALL Mal, T-cell differentiation protein-like
Metal ion transport 3.39E-02 A_70_P030126 −2.36 1.24 CP* Ceruloplasmin (ferroxidase) [10,16]
CUST_12632_PI375351158 2.28 1.50 KCTD12 Potassium channel tetramerisation domain containing 12
A_70_P027206 2.15 2.10 SLC30A1 Solute carrier family 30 (zinc transporter), member 1 [10,11]
A_70_P050456 −2.65 −1.58 SLC38A10 Solute carrier family 38, member 10
Antimicrobial 5.05E-02 CUST_139_PI396851701 15.26 −1.74 CATHL1 Cathelicidin 1
CUST_3993_PI375351158 5.96 −1.25 S100A8 S100 calcium binding protein A8 [10]
Apoptosis 5.45E-02 CUST_260_PI396851701 −2.04 −1.55 CARD6 Caspase recruitment domain family, member 6
A_70_P022526 −2.29 −1.16 OPA1 Optic atrophy 1 (autosomal dominant)
A_70_P049526 −1.12 −2.70 PERP PERP, TP53 apoptosis effector
A_70_P069836 −3.14 −1.31 RNF130 Ring finger protein 130
A_70_P067091 −2.90 −1.55 UBE2Z Ubiquitin-conjugating enzyme E2Z
Immunoglobulin-like fold 5.55E-02 A_70_P036361 2.06 2.09 CD1E CD1e molecule
CUST_9656_PI375351158 −2.03 1.11 FGFR2 Fibroblast growth factor receptor 2
CUST_12141_PI375351158 2.64 −1.00 IGK Ig kappa chain
A_70_P016986 −2.23 1.16 TRD@ T cell receptor delta locus [11]
Secreted 5.70E-02 A_70_P048761 1.34 −2.27 SPINK5 Serine peptidase inhibitor, Kazal type 5
CUST_9580_PI375351158 1.13 −2.49 MMRN1 Multimerin 1
CUST_10101_PI375351158 −1.07 −2.53 NPNT Nephronectin
A_70_P034356 2.88 1.19 SEMA3G Sema domain, immunoglobulin domain (Ig), short basic
domain, secreted, (semaphorin) 3G
A_70_P063891 2.38 −1.22 PCOLCE2 Procollagen C-endopeptidase enhancer 2
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Table 2 GO terms for differentially expressed genes (Continued)
GTP binding 7.49E-02 A_70_P019676 4.33 1.16 ACSM1 Acyl-CoA synthetase medium-chain family member 1 [10]
A_70_P046951 −2.24 −1.02 ARL4C ADP-ribosylation factor-like 4C
A_70_P008796 −2.06 1.15 DOCK11 Dedicator of cytokinesis 11
A_70_P000126 −3.63 −1.82 GBP4 Guanylate binding protein 4
Disulfide bond 7.58E-02 A_70_P018376 2.56 −1.08 FAP Fibroblast activation protein, alpha
A_70_P041321 −2.15 −2.57 IGHA2 Immunoglobulin heavy constant alpha 2 (A2m marker)
Structural molecule activity 8.04E-02 A_70_P028306 −2.03 −1.05 LMNB1 Lamin B1
CUST_13373_PI375351158 −2.15 −1.29 LOC531679 Ribosomal protein 17-like; similar to 60S ribosomal
Protein L17 (L23); similar to ribosomal protein L17;
similar to Rpl17 protein; similar to mCG3798
CUST_7057_PI375351158 −2.33 −1.07 LOC789587 Similar to Ribosomal_L22 domain containing protein RGD1359290
A_70_P031441 −2.43 −1.79 VCL Vinculin [11]
Positive regulation of
inflammatory response
9.48E-02 A_70_P058551 8.25 −1.12 FABP4 Fatty acid binding protein 4, adipocyte
CUST_9779_PI375351158 −1.40 −2.38 IDO1 Indoleamine 2,3-dioxygenase 1
Other CUST_13467_PI375351158 1.29 −2.14 FBP2 Fructose-1,6-bisphosphatase 2
A_70_P055306 2.77 1.50 SLC43A1 Solute carrier family 43, member 1
A_70_P049406 −1.99 −2.32 EIF5 Eukaryotic translation initiation factor 5 [11]
A_70_P070931 −2.87 −1.18 NUDT19 Nudix (nucleoside diphosphate linked moiety X)-type motif 19
A_70_P036101 1.22 −3.18 NOP10 NOP10 ribonucleoprotein homolog (yeast) [11]
A_70_P011091 −2.74 −2.01 PFDN2* Prefoldin subunit 2
A_70_P039656 17.20 −1.52 BAC5 5 kDa bactinecin precursor
A_70_P061341 −1.03 −2.94 C11ORF10 Chromosome 11 open reading frame 10
A_70_P061266 2.36 1.03 C5ORF43 Chromosome 5 open reading frame 43
A_70_P051377 14.99 −1.48 CATHL1B Procyclic dodecapeptide
A_70_P015101 −2.70 −1.03 CCDC82 Coiled-coil domain containing 82
A_70_P012541 −1.02 −2.36 CNN1 Calponin 1, basic, smooth muscle
A_70_P002841 2.03 1.48 EPAS Endothelial PAS domain protein 1
A_70_P008841 −2.18 −1.23 EPSTI1 Epithelial stromal interaction 1 (breast)
A_70_P060756 −2.12 1.08 FAM190B KIAA1128
A_70_P062951 2.05 1.12 FNDC3B Fibronectin type III domain containing 3B [33]
A_70_P051181 2.76 1.28 HSD11K NAD-dependent 11-beta-hydroxysteroid dehydrogenase
CUST_46_PI396851701 −2.06 −2.15 IGHA Immunoglobulin heavy constant alpha
A_70_P024671 2.46 1.31 INHBB Inhibin, beta B
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Table 2 GO terms for differentially expressed genes (Continued)
A_70_P033656 −2.34 −1.77 ISG12(A) ISG12(a) protein-like
A_70_P012537 −2.19 −3.58 LGALS15 Galectin 15
CUST_3620_PI375351158 −1.58 −2.22 LGALS16 Beta-galactoside-binding lectin
A_70_P020131 −1.10 −3.84 LGALS9C Lectin, galactoside-binding, soluble, 9C
CUST_6089_PI375351158 −2.02 −1.71 LOC100140018 Similar to cytochrome P450, family 2, subfamily J
A_70_P016801 −2.20 −1.48 LOC443321 Lysozyme 2a precursor
A_70_P026671 −1.91 −2.05 LOC524810 IgM
A_70_P023026 3.09 1.74 LOC615697 Similar to cytochrome P450
A_70_P039266 −2.03 −1.83 LOC654331 Pancreatitis-associated protein I [10]
A_70_P039271 −3.94 −7.40 MCP-4 Mast cell proteinase-4
CUST_11558_PI375351158 2.00 2.23 MGC140754 Hypothetical LOC508613
CUST_9725_PI375351158 −2.26 −3.77 PLAC8 Placenta-specific 8
CUST_10114_PI375351158 2.56 1.15 RN18S1 18S ribosomal RNA
A_70_P030132 −2.40 −1.71 RTP4 Receptor (chemosensory) transporter protein 4 [34]
A_70_P030426 10.95 1.39 SC5 Cathelin-related prepropeptide
*Genes selected for validation by quantitative RT-PCR.
BLAST results for clones exhibiting significant alterations in gene expression (P ≤ 0.05 and ≥ 2-fold change) in preclinical and clinical stages of natural scrapie. The GO was determined using DAVID Bioinformatics
Resources 6.7 (NIAID/NIH, USA), an on-line functional annotation tool. Only genes with a known GO are shown. (C, Clinical; FC, Fold change; NC, Negative control; PC, Preclinical). Previous studies describing altered
expression of the differentially expressed genes reported here in the brain and lymphoid tissues of experimentally-infected sheep are cited.
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Table 3 Signaling pathways associated with differentially expressed genes
Term P value ProbeName FC (C vs NC) FC (PC vs NC) Gene
symbol
Gene name
PPAR signaling
pathway
1.88E-02 CUST_598_PI375351158 2.28 1.33 FABP5 Fatty acid binding protein 5 (psoriasis-associated)
CUST_8730_PI375351158 1.06 −2.05 ACSL4 Acyl-CoA synthetase long-chain family member 4
A_70_P058551 8.25 −1.12 FABP4 Fatty acid binding protein 4, adipocyte
A_70_P039986 −1.27 2.39 SLC27A2 Solute carrier family 27 (fatty acid transporter),
member 2
ECM-receptor
interaction
2.53E-02 A_70_P021711 −2.19 −1.69 COL1A1 Collagen, type I, alpha 1
A_70_P058626 2.27 1.13 VWF von Willebrand factor
A_70_P016337 −1.78 −2.72 HMMR Hyaluronan-mediated motility receptor (RHAMM)
Focal adhesion 6.73E-02 A_70_P021711 −2.19 −1.69 COL1A1 Collagen, type I, alpha 1
A_70_P058626 2.27 1.13 VWF von Willebrand factor
A_70_P050922 2.19 −1.06 VEGFA Vascular endothelial growth factor A
A_70_P031441 −2.43 −1.79 VCL Vinculin
Signaling pathways with which differentially expressed genes (P ≤ 0.05 and ≥ 2-fold change) are associated were identified by enrichment analysis using the
on-line functional annotation (DAVID Bioinformatics Resources 6.7; NIAID/NIH, USA). (C, Clinical; FC, Fold change; NC, Negative control; PC, Preclinical).
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http://www.biomedcentral.com/1471-2164/15/59found that gene encoding decorin (DCN), a protein lo-
cated in the extracellular matrix, was overexpressed in
scrapie animals, in line with previous reports of DCN
upregulation at both the gene and protein level in cells
isolated from scrapie-infected mouse spleen [16]. Our
results confirm the differential regulation of DCN in the
MLN of sheep with natural scrapie. Some of differen-
tially transcribed genes that we identified encode pro-
teins that may be involved in the pathogenesis of protein
misfolding diseases. Examples include proteins involved
in disulfide bonding, GTP binding and protein dimeriza-
tion. Differential expression of some of these genes has
been reported in other tissues in scrapie-infected mice
[12,14,38] and in natural scrapie [10,11].
The GO enrichment analysis of our microarray data
identified 3 signaling pathways that may be involved in
the pathogenesis of scrapie; extracellular matrix (ECM)-
receptor interaction, focal adhesion and the peroxisome
proliferator-activated receptor (PPAR) signaling pathway.
We and others have previously reported altered expres-
sion of COL1A2, COL3A1 and COL12A1 and other
ECM related genes in the CNS of sheep infected with
scrapie and other prion diseases [10,11,39,40] and in
leukocyte-depleted splenic cells from scrapie-infected
mice [16]. Moreover, prion protein regulates β1 integrin
signaling activity in prion-infected neurons [41] and the
expression of genes of the PPAR signaling pathway is al-
tered in Alzheimer’s disease (AD) [42,43]. Our findings
indicate alterations in the extracellular matrix, focal ad-
hesion and in fatty acid metabolism via the PPAR signal-
ing pathway in non-neural tissues susceptible to prion
infection.
In addition to analyzing differential gene expression,
we investigated the effect of prion deposition on LRS
gene expression in order to further our understanding ofthe prion-specific pathogenic pathways in scrapie. Two
regression models (see Methods section) were used to
identify possible associations between gene expression
data and the PrPSc deposition score, as determined by
immunohistochemistry. These statistical association ap-
proaches can identify genes that may be implicated in
prion-specific processes, although the differences in their
expression levels between control and infected animals
were not significant. Except for CLTA, none of the genes
identified in the association analysis exhibited significant
differences in expression in the array data. The gene
ontology analysis revealed that genes associated with
prion deposition are involved in DNA binding, the gen-
eration of precursor metabolites and energy, ion binding,
catabolic processes and kinase functions. Among the
genes that were closely associated with prion protein de-
position were cathepsin K (CTSK) and clathrin, light
chain A (CLTA). Several members of the cathepsin family
(including cathepsins C, D, H, S and Z) are differentially
expressed in prion-affected brain tissues [12,14,38,44,45].
We observed a negative association between CTSK expres-
sion and prion deposition, suggesting a possible proteolytic
effect of cathepsin K on prion protein. Furthermore, CLTA
expression was negatively associated with prion depos-
ition. The expression of this gene is also altered in many
neurodegenerative diseases such as Alzheimer’s and
Huntington’s diseases [46,47], and clathrin-mediated path-
ways are intimately involved in amyloid formation in
neurodegenerative diseases [48]. These observations sug-
gest that CLTA may also be involved in prion amyloid
formation.
Seven of the differentially expressed genes detected
were selected for further analysis by qRT-PCR. These
genes were chosen based on their involvement in protein
misfolding pathways (PFDN2, UCHL1 and PSMA7), the
Figure 2 Condition trees generated by cluster analysis. A
hierarchical cluster analysis (Euclidean distance clustering algorithm)
was performed using PermutMatrix [21], which identified 139 genes
whose expression differed significantly (≥ 2 fold change with
respect to controls) in at least at one of the 2 disease stages
analyzed (preclinical and clinical). Colors represent the level of
expression. Sample information is listed across the top. The names
of the known genes are indicated. Note the distinct patterns of
gene expression in control, preclinical and clinical animals.
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metabolism and neurotoxicity (CP) and antioxidant
mechanisms (BBOX1). Comparable fold changes in the
expression of all 7 genes, in both preclinical and clinical
disease stages, were observed in the microarray and
qRT-PCR analyses, confirming the validity of both the
array data and the alignment analysis.
Here, we will briefly discuss how these genes may be
involved in PrPSc formation, dissemination and toxicity
and in the response of the organism to prion infection.
Genes encoding proteins involved in molecular pathways
that regulate protein misfolding (PSMA7, UCHL1 and
PFDN2) were downregulated in scrapie-infected animals.
Furthermore, our association study revealed a positive
association between proteasome subunit, beta type, 8
(PSMB8) and PrPSc deposition. The proteins encoded by
PSMA7, UCHL1 and PSMB8 form part of the ubiquitin
proteasome system (UPS), a complex that regulates the
degradation of incomplete, damaged or misfolded pro-
teins [49,50]. The UCHL1 protein has been implicated
in protein misfolding diseases. UCHL1 is abundantly
expressed in nervous system tissues [51], and gene vari-
ants and changes in the activity of UCHL1 have been as-
sociated with neurodegenerative disorders such as
Alzheimer’s, Parkinson’s and Huntington’s diseases
[27,52-55]. In prion diseases, the functional capacity of
the UPS is impaired by the direct interaction of β-sheet-
rich PrP with the 20S core particle of the proteasome
complex, inhibiting substrate entry [56]. UPS impair-
ment may enable the conversion of cytosolic PrPC to an
abnormal, “PrPSc-like” form [57]. Increased levels of ubi-
quitin conjugates are found in scrapie-infected mouse
brains, and are correlated with decreased proteasome
function [58]. The downregulation of PSMA7 and
UCHL1 genes and the positive association of PrPSc de-
position with PSMB8 expression in both preclinical and
clinical stages of natural scrapie in the LRS of sheep is in
line with the impaired proteasome function described in
prion diseases of the nervous system [28]. Moreover,
prefoldin (PFD) is likely to bind to substrate proteins
that exist in an unfolded state and to transfer these pro-
teins to the cytosolic chaperonin-containing TCP-1
(CCT) for functional folding [59]. The role of this pro-
tein in protein misfolding diseases has been investigated
Figure 3 Confirmation of microarray results by quantitative real-time PCR. Differential expression of selected genes analyzed by microarray
and quantitative RT-PCR in mesenteric lymph node samples from preclinical and clinical scrapie sheep: gamma-butyrobetaine hydroxylase
(BBOX1), ceruloplasmin (CP), prefoldin subunit 2 (PFDN2), proteasome subunit alpha type-7 (PSMA7), plasminogen activator inhibitor-1 (SERPINE1),
ubiquitin carboxy-terminal hydrolase L1 (UCHL1), and vascular endothelial growth factor (VEGFA).
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AD [60]. Our findings reveal downregulation of PFDN2
expression in both preclinical and clinical stages of nat-
ural scrapie in the LRS of sheep. The observed downreg-
ulation of PSMA7 and UCHL1 may facilitate prion
conversion, implicating these genes in the pathogenic
mechanism of the scrapie.
The expression of SERPINE 1 or plasminogen activator
inhibitor-1 (PAI-1) was downregulated in preclinical scra-
pie animals and upregulated in the clinical phase of the
disease, suggesting a dual role for this gene in scrapie.
SERPINE1 is an inhibitor of 2 types of plasminogen acti-
vators; tissue-type plasminogen (tPA) and urokinase-type
plasminogen (uPA) activators. Plasminogen was recently
show to stimulate PrP misfolding by accelerating the
conversion of PrPC to PrPSc [26]. The downregulation of
SERPINE1 in preclinical scrapie may inhibit PrPSc forma-
tion in the early stages of the disease. SERPINE1 is also in-
volved in angiogenesis, as evidenced by the defective
angiogenesis seen in tumor-bearing SERPINE1-deficient
mice [61]. Accordingly, decreased expression of SERPINE1
may represent a protective response to PrPSc propagation
during the preclinical stage of natural scrapie. However,
we observed a slight increase in SERPINE1 expression in
clinical scrapie-infected sheep as compared with controls
(FC = 1.25). The expression of vascular endothelial growth
factor (VEGF, also known as VEGFA), which is also in-
volved in angiogenesis, was altered in scrapie. This gene
mediates a critical rate-limiting step in physiological
angiogenesis and plays a key role in tumor progression
and angiogenesis and its expression by primary tumor
promotes lymphangiogenesis and facilitates metastasis to
sentinel lymph nodes [62]. As observed for SERPINE1, wedetected a slight decrease in VEGFA expression in lymph-
atic tissues in the preclinical stage of natural scrapie,
followed by a moderate increase during the clinical stage
of the disease. Lymphatic vessels are one of the proposed
routes of prion dissemination [63]. Accordingly, the differ-
ential regulation of SERPINE1 and VEGFA observed in
scrapie may reflect a role in prion propagation. However,
further studies will be necessary to clarify the role of these
proteins in prion dissemination.
In addition to genes involved in prion misfolding and
propagation, we analyzed the expression of the cerulo-
plasmin (CP) gene, which is involved in neurotoxicity.
CP is a ferroxidase that contains 95% of the copper
present in blood plasma, and is thus a key mediator of
copper transport and metabolism [64]. Copper plays an
important role in prion integrity; in vitro, copper en-
hances renaturation and stabilization of PrPSc, restoring
protease resistance and infectivity [64]. Increased CP ex-
pression has been reported in leukocyte-depleted splenic
cells from clinical scrapie-infected mice [16]. However,
we found that CP expression was significantly downreg-
ulated in the lymph nodes of scrapie-infected animals in
the clinical stage of the disease. In patients with acerulo-
plasminemia, the predominant clinical symptoms are
neurologic and include dystonia, dysarthria, and subcor-
tical dementia due to progressive degeneration of the
basal ganglia, as well as selective neuronal loss and in-
creased iron content in the microglia, neurons and basal
ganglia [29]. Ceruloplasmin also plays an essential role
in normal brain iron metabolism and protects against
neuronal loss [65]. Our findings suggest that CP defi-
ciency may contribute to the neuronal degeneration ob-
served in scrapie, although further analyses of brain
Term Gene symbol Gene name P1 P2 Slope of regression
CTTNBP2NL CTTNBP2 N-terminal like 1,50E-02 3,06E-03
MYL12B Myosin, light chain 12B, regulatory 1,30E-02 2,09E-02
TBCC Tubulin folding cofactor C 1,48E-02 3,18E-02
H2AFY Core histone macro-H2A 1,65E-03 1,52E-02
TSPYL4 TSPY-like 4 1,25E-02 3,24E-02
ANAPC13 Anaphase promoting complex subunit 13 2,87E-02 4,89E-02
ERCC2 Excision repair cross-complementing,  group 2 4,78E-02 8,36E-03
KCMF1 Potassium channel modulatory factor 1 1,37E-02 1,88E-02
PSMB8 Proteasome subunit, beta type, 8 4,09E-03 2,16E-02
WWP2 WW domain containing E3 ubiquitin protein ligase 2 2,27E-03 1,81E-02
LATS1 LATS, large tumor suppressor, homolog 1 (Drosophila) 3,24E-02 1,79E-02
NME2 NME/NM23 nucleoside diphosphate kinase 2 1,66E-03 3,32E-03
RPL22 Ribosomal protein L22 4,81E-02 3,93E-02
ATF6B Activating transcription factor 6 beta 4,95E-02 7,44E-03
NFYA Nuclear transcription factor Y, alpha 3,44E-02 4,80E-02
PDZD11 PDZ domain containing 11 6,97E-03 1,12E-02
PUF60 Poly-U binding splicing factor 60KDa 3,98E-02 3,73E-02
RORA RAR-related orphan receptor A 4,74E-02 3,84E-02
TSC22D2 TSC22 domain family, member 2 4,56E-02 3,28E-02
Extracellular region B2M Ovis aries beta-2-microglobulin 2,28E-02 3,85E-02
Extracellular region PDE3B Phosphodiesterase 3B, cGMP-inhibited 1,78E-02 1,79E-02
ATP5G1 ATP synthase, subunit C1 (subunit 9) 1,28E-02 1,90E-02
NDUFB5 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 5 2,00E-02 1,34E-02
PDHA1 Pyruvate dehydrogenase (lipoamide) alpha 1 2,64E-02 2,94E-02
TPI1 Triosephosphate isomerase 1 1,38E-02 1,77E-02
Integral to membrane FAM73B Family with sequence similarity 73, member B 2,31E-02 4,51E-02
HARBI1 Harbinger transposase derived 1 2,57E-02 1,35E-02
SNRPC Small nuclear ribonucleoprotein polypeptide C 7,02E-03 5,39E-03
SRI Sorcin 1,55E-02 4,61E-03
ZBTB34 Zinc finger and BTB domain containing 34 2,34E-02 3,81E-02
ZC3HC1 Zinc finger, C3HC-type containing 1 8,47E-03 4,41E-02
EEF2K Eukaryotic elongation factor-2 kinase 1,50E-02 4,53E-02
PFKP Phosphofructokinase, platelet 2,71E-02 2,61E-02
PHKA1 Phosphorylase kinase, alpha 1 (muscle) 3,13E-02 3,37E-02
SLK STE20-like kinase (yeast) 3,63E-02 4,25E-02
CDK2AP2 Cyclin-dependent kinase 2 associated protein 2 2,78E-02 2,16E-02
CXCL12 Chemokine (C-X-C motif) ligand 12 1,91E-02 1,99E-02
ASXL2 Similar to additional sex combs like 2 2,93E-02 4,92E-03
FEM1B Fem-1 homolog b (C. elegans) 2,85E-03 3,25E-03
Metal-binding GRAMD1C GRAM domain containing 1C 9,71E-04 2,52E-02
CHCHD3 Coiled-coil-helix-coiled-coil-helix domain containing 3 4,25E-03 1,95E-02
DUT Deoxyuridine triphosphatase 2,20E-02 1,14E-02
MRPL22 Mitochondrial ribosomal protein L22 3,15E-02 8,44E-03
TIMM10 Translocase of inner mitochondrial membrane 10 1,54E-02 2,46E-02
CENPT Centromere protein T 1,84E-02 2,65E-02
GAPT GRB2-binding adaptor protein, transmembrane 1,07E-02 3,88E-02
ZWINT ZW10 interactor 2,97E-02 3,24E-02
GMPS Guanine monphosphate synthetase 4,90E-02 4,87E-02
GSPT1 G1 to S phase transition 1 2,62E-02 3,21E-02
RECQL4 RecQ protein-like 4 2,97E-02 1,04E-02
CLTA Clathrin, light chain A 1,42E-03 3,84E-02
XPO7 Exportin 7 2,51E-02 1,32E-02
DUSP10 Dual specificity phosphatase 10 2,27E-03 1,99E-02
MPST Mercaptopyruvate sulfurtransferase 1,53E-02 3,51E-02
Protein localization TMSB10 Thymosin beta 10 7,12E-03 1,61E-02
Protein serine/threonine kinase activity IgFBp3 Insulin-like growth factor binding protein 3 3,38E-03 4,03E-02
SFT2D2 SFT2 domain containing 2 1,50E-02 3,26E-02
SNX13 Sorting nexin 13 4,43E-02 3,68E-02
TMX4 Thioredoxin-related transmembrane protein 4 3,23E-02 1,32E-02
Proteolysis CTSK Cathepsin K 1,67E-03 4,85E-02
Regulation of apoptosis NAPA N-ethylmaleimide-sensitive factor attachment protein, alpha 1,41E-02 2,30E-02
Transferase PRDM4 PR domain containing 4 3,99E-02 4,83E-02
INSIG2 Insulin induced gene 2 1,72E-02 1,78E-02
KCTD1 Potassium channel tetramerisation domain containing 1 4,41E-02 3,66E-02
OST4 Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit 4 3,27E-03 3,05E-02
PFDN1 Prefoldin subunit 1 3,58E-02 3,96E-02
SLC44A1 Solute carrier family 44, member 1 4,85E-03 4,03E-02
BROX BRO1 domain and CAAX motif containing 3,26E-02 3,32E-02
CNOT10 CCR4-NOT transcription complex, subunit 10 3,63E-02 1,46E-02
COPS4 COP9 constitutive photomorphogenic homolog subunit 4 (Arabidopsis) 1,93E-02 4,12E-02
DYNC1I2 Dynein, cytoplasmic 1, intermediate chain 2 2,39E-02 3,24E-02
GID8 GID complex subunit 8 homolog (S. cerevisiae) 1,63E-02 1,54E-02
KBTBD4 Kelch repeat and BTB (POZ) domain containing 4 4,37E-02 4,47E-02
KIAA2026 KIAA2026 ortholog 1,83E-02 9,76E-03
LOC100037674 Thymidylate synthetase 2,60E-02 3,98E-02
LOC100847238 Uncharacterized LOC100847238 3,34E-02 2,43E-02
LOC101103408 Uncharacterized LOC101103408 4,49E-02 3,87E-02
LOC101105790 Keratin-associated protein 15-1-like 3,97E-02 4,62E-02
LOC101105958 Non-histone chromosomal protein HMG-17-like 9,15E-03 3,40E-02
LOC101108110 Prothymosin alpha-like 1,86E-02 2,06E-03
LOC101109747 Mamu class II histocompatibility antigen, DR alpha chain-like 1,08E-03 4,13E-03
LOC101110664 Cytochrome c oxidase subunit 5B, mitochondrial-like 4,47E-03 2,11E-02
LOC101114533 10 kDa heat shock protein, mitochondrial-like 4,48E-02 4,62E-02
LOC101115083 Glutathione S-transferase omega-1-like 3,77E-03 3,53E-02
LOC101117272 Caspase-13-like 1,28E-02 2,94E-02
LOC101119517 Interferon-induced guanylate-binding protein 1-like 1,68E-02 1,81E-02
LOC101121538 Cytochrome c oxidase subunit 6B1-like 1,35E-02 8,38E-03
LOC101123112 60S ribosomal protein L23a-like 3,36E-02 9,56E-03
LOC523454 Protein WWC3-like 4,34E-02 1,57E-02
MYO18A Myosin XVIIIA 2,30E-02 4,81E-02
PAIP1 Poly(A) binding protein interacting protein 1 1,66E-02 9,24E-03
PPIA Peptidylprolyl isomerase A 1,65E-02 7,53E-03
SECISBP2L SECIS binding protein 2-like 1,36E-02 2,15E-02
SERBP1 SERPINE1 mRNA binding protein 1 3,82E-02 1,94E-02
SMU1 Smu-1 suppressor of mec-8 and unc-52 homolog (C. elegans) 4,77E-02 1,38E-02
TSR2 TSR2, 20S rRNA accumulation, homolog (S. cerevisiae) 1,75E-02 1,77E-02
Other
Nucleotide binding
Organelle envelope
Phosphorus metabolic process
Protein transport
Transmembrane region
Transport
Ion binding
Kinase
Lymphocyte activation
Metal ion binding
Mitochondrion
Non-membrane-bounded organelle
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Figure 4 (See legend on next page.)
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Figure 4 Relationship between gene expression profiles and PrPSc deposition. Figure shows genes whose expression was statistically
associated with PrPSc deposition. P1 is the probability calculated using the simple regression model yi = μ + bpi + ei, and P2 is the probability
calculated using the second regression model yij = μ + Ti + bpij + eij (which includes a systematic effect associated with the 3 categories; Preclinical,
Clinical and Healthy). The slope of regression describing the relationship between histopathological lesions and gene expression was calculated
using the second model. Analyses were performed using R software (R project for Statistical Computing).
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termine its role in scrapie.
We detected upregulation of gamma-butyrobetaine hy-
droxylase (BBOX1), a gene involved in the response of
the organism to oxidative stress. BBOX1 is the enzyme
responsible for the biosynthesis of L-carnitine, a mol-
ecule involved in fatty acid metabolism with important
anti-free radical and antioxidant activities [66]. The acet-
ylated form of L-carnitine (acetyl-L-carnitine) has been
proposed as a potential treatment for neurodegenerative
diseases, including AD [30]. Our results demonstrate up-
regulation of BBOX1 in both clinical and preclinical
stages of scrapie in the LRS, perhaps reflecting an in-
crease in the levels of antioxidant molecules (L-carnitine
and acetyl-L-carnitine) in response to the damage in-
duced by the prion.
The known functions of the genes that were up- and
downregulated in scrapie suggest potential roles in the
pathogenesis of prion diseases. However, we cannot rule
out the possibility that these changes in expression are a
secondary response of the organism to the disease. The
findings of this transcriptomic analysis thus need to be
complemented by further studies analyzing the cellular
localization, protein levels and function of the genes of
interest in order to establish their specific roles in prion
diseases.
Conclusions
Our genome-wide expression analysis of the LRS of
sheep with natural scrapie, at both preclinical and clin-
ical stages of the disease, has identified new genes that
may be involved in the pathogenesis of scrapie. We con-
firmed the differential expression of 7 genes involved in
prion or other neurodegenerative diseases. The down-
regulation of genes involved in repairing misfolded pro-
teins (PFDN2, PSMA7 and UCHL1) may contribute to
prion formation. Furthermore, the altered expression of
genes that promote angiogenesis in the lymph nodes
(SERPINE1 and VEGFA) may facilitate prion dissemin-
ation, while the observed decrease in CP expression may
contribute to prion toxicity. Our results confirm the al-
tered expression of BBOX1, a gene implicated in the
systemic response of the organism to prion-induced oxi-
dative stress, in scrapie infected animals. Although fur-
ther studies are necessary to determine the specific roles
of these genes in the pathogenesis of prion diseases, our
findings represent an important first step towardsidentifying candidate genes that may serve as useful bio-
markers for the development of early diagnostic tools
and therapeutic strategies for scrapie.
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